摘要
目的：探讨卡维地洛联合螺内酯治疗老年人慢性心力衰竭的临床疗效，为临床治疗方案的制定提供参考。方法选取老年慢性心力衰竭患者104例，按照数字表法将患者随机分为观察组和对照组各52例。对照组按照慢性心力衰竭常规治疗方案进行干预，观察组在常规方案的基础上，加用卡维地洛联合螺内酯口服治疗。治疗6个月后对比两组患者的临床疗效，同时对比两组患者治疗前后的超声心动图检查结果以及治疗过程中的不良反应发生情况。结果观察组的显效率为59．62％，总有效率为96．15％，均显著高于对照组（χ2＝4．10、9．82，均 P ＜0．05）；两组患者治疗后的 LVEDD、LVESD 均显著低于治疗前[（51．89±7．06）mm、（41．39±6．85）mm、（60．71±7．43）mm、（51．02±7．95）mm]，而 LVEF[（52．31±9．02）％、（41．64±7．73）％]均显著高于治疗前（t ＝4．92、5．10、5．45、2．87、2．98、3．03，均 P ＜0．05）；观察组治疗后的 LVEDD 为（51．89±7．06）mm，LVESD 为（41．39±6．85）mm，均显著低于对照组，而 LVEF 为（52．31±9．02）％，显著高于对照组（t ＝3．02、2．98、2．97，均 P ＜0．05）；两组患者治疗过程中不良反应发生率差异无统计学意义（P ＞0．05）。结论卡维地洛联合螺内酯可显著提高老年慢性心力衰竭患者的临床治疗效果，有效改善患者的心室重构，提高患者的心肌收缩力，且具有良好的安全性。
Objective To investigate the effect of carvedilol combined with spironolactone in the treatment of elderly patients with chronic heart failure clinical efficacy and to provide reference for clinical treatment of formulation. Methods 104 elderly patients with chronic heart failure were randomly divided into observation group and control group,52 cases were randomly divided into observation group and control group.Control group intervention in accord-ance with the conventional treatment of chronic heart failure program,the observation group in the conventional scheme based on,combined with oral carvedilol and spironolactone therapy.6 months after treatment,clinical efficacy was compared between the two groups.The results of echocardiography before and after treatment in two groups were compared.The adverse reactions in the treatment process were compared.Results The effective rate in the observation group was 59.62%,the total effective rate was 96.15%,which were significantly higher than those of the control group （χ2 =4.10,9.82,all P 〈0.05）;After treatment,LVEDD and LVESD of the two groups were significantly lower than those before treatment[（51.89 ±7.06）mm,（41.39 ±6.85）mm,（60.71 ±7.43）mm,（51.02 ±7.95）mm], LVEF[（52.31 ±9.02）% and （41.64 ±7.73）]were significantly higher than that before treatment,there were statistifically significant differences between the two groups（t =4.92,5.10,5.45,2.87,2.98,3.03,all P 〈0.05）;After treatment,LVEDD[（51.89 ±7.06 ）mm],LVESD [（41.39 ±6.85 ）mm]of the observation group were significantly lower than those of the control group,and LVEF（52.31 ±9.02）% were significantly higher than that of the control group,there were statistifically significant differences between the two groups （t =3.02,2.98,2.97,all P 〈0.05）;There was no significant difference in the incidence of adverse reactions between the two groups（P 〉0.05）.Conclusion Carvedilol combined with spironolactone can significantly improve the clinical effect of the
出处
《中国基层医药》
CAS
2016年第15期2324-2327,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
卡维地洛
螺内酯
老年
慢性心力衰竭
Carvedilol
Spironolactone
Elderly
Chronic heart failure
